Ligand Pharmaceuticals posts Q1 2026 revenue $51.7M and adjusted EPS $1.63, reaffirms raised 2026 guidance
- Q1 2026 results driven by 56% royalty growth, contributing to revenue of $51.7 million
- Company reaffirms previously raised 2026 guidance, including partial-year contribution from pending XOMA Royalty acquisition
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.